Zobrazeno 1 - 10
of 397
pro vyhledávání: '"Quimioteràpia"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J. A. de Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip Y. F. L. de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. M. Schellens, Christoph C. Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung-Jue Bang
Publikováno v:
Nature medicine, vol 29, iss 5
Scientia
Nature Medicine, 29(5), 1103-1112. Nature Publishing Group
Scientia
Nature Medicine, 29(5), 1103-1112. Nature Publishing Group
BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in eight cohorts of patients with BRAFV600E-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c4ebaa45d1da62d0ac5f9e5a60659de
http://www.scopus.com/inward/record.url?scp=85152683237&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85152683237&partnerID=8YFLogxK
Autor:
Piedad Herrera-Ramírez, Sarah Alina Berger, Dana Josa, David Aguilà, Ana B. Caballero, Pere Fontova, Vanessa Soto-Cerrato, Manuel Martínez, Patrick Gamez
Publikováno v:
JBIC Journal of Biological Inorganic Chemistry. 28:403-420
Two ruthenium(II) polypyridyl complexes were prepared with the {Ru(phen)2}2+ moiety and a third sterically non-hindering bidentate ligand, namely 2,2′-dipyridylamine (dpa) and N-benzyl-2,2′-dipyridylamine (Bndpa). Hence, complexes [Ru(phen)2(dpa)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c714588ad04f0e89c7e9142a37271351
https://doi.org/10.1007/s00775-023-01998-z
https://doi.org/10.1007/s00775-023-01998-z
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Luis G. Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, Jaafar Bennouna, Michael Schenker, Ying Cheng, Oscar Juan-Vidal, Hideaki Mizutani, Alejo Lingua, Felipe Reyes-Cosmelli, Niels Reinmuth, Juliana Menezes, Jacek Jassem, Svetlana Protsenko, Eduardo Richardet, Enriqueta Felip, Kynan Feeney, Bogdan Zurawski, Aurelia Alexandru, Emmanuel de la Mora Jimenez, Shaker Dakhil, Shun Lu, Martin Reck, Thomas John, Nan Hu, Xiaoqing Zhang, Judi Sylvester, Laura J. Eccles, Diederik J. Grootendorst, David Balli, Jaclyn Neely, David P. Carbone
Publikováno v:
Scientia
Non–small cell lung cancer; Brain metastases; Somatic mutations Càncer de pulmó de cèl·lules no petites; Metàstasis cerebrals; Mutacions somàtiques Cáncer de pulmón de células no pequeñas; Metástasis cerebrales; Mutaciones somáticas Int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1273c44ad3440298c0d6bb6ae78e198
https://doi.org/10.1016/j.jtho.2022.10.014
https://doi.org/10.1016/j.jtho.2022.10.014
Autor:
Cora N. Sternberg, Daniel P. Petrylak, Joaquim Bellmunt, Hiroyuki Nishiyama, Andrea Necchi, Howard Gurney, Jae-Lyun Lee, Michiel S. van der Heijden, Eli Rosenbaum, Nicolas Penel, See-Tong Pang, Jian-Ri Li, Xavier García del Muro, Florence Joly, Zsuzsanna Pápai, Weichao Bao, Peter Ellinghaus, Chengxing Lu, Mitchell Sierecki, Sabine Coppieters, Keiko Nakajima, Tatiane Cristine Ishida, David I. Quinn
Publikováno v:
Journal of Clinical Oncology. 41:629-639
PURPOSE Rogaratinib, an oral pan-fibroblast growth factor receptor (FGFR1-4) inhibitor, showed promising phase I efficacy and safety in patients with advanced urothelial carcinoma (UC) with FGFR1-3 mRNA overexpression. We assessed rogaratinib efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc755d9c3cfa6ea9c4e87d64f27f4dcc
https://doi.org/10.1200/jco.21.02303
https://doi.org/10.1200/jco.21.02303
Autor:
Ana Oaknin, Bradley J. Monk, Ignace Vergote, Andreia Cristina de Melo, Yong-Man Kim, Alla S. Lisyanskaya, Vanessa Samouëlian, Hee Seung Kim, Evgeniy A. Gotovkin, Fernanda Damian, Chih-Long Chang, Shunji Takahashi, Jingjin Li, Melissa Mathias, Matthew G. Fury, Cristina Ivanescu, Matthew Reaney, Patrick R. LaFontaine, Israel Lowy, James Harnett, Chieh-I Chen, Krishnansu S. Tewari
Publikováno v:
Scientia
Chemotherapy; Quality of life; Symptoms Quimioterapia; Calidad de vida; Síntomas Quimioteràpia; Qualitat de vida; Símptomes Background In a phase III, randomised, active-controlled study (EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9; R2810-ONC-1676; NCT0
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7902ba76c90b86f4278bb8b41600848
https://doi.org/10.1016/j.ejca.2022.03.016
https://doi.org/10.1016/j.ejca.2022.03.016
Autor:
Josep Tabernero, Paulo M. Hoff, Lin Shen, Atsushi Ohtsu, Manish A. Shah, Asna Siddiqui, Sarah Heeson, Astrid Kiermaier, Harrison Macharia, Eleonora Restuccia, Yoon-Koo Kang
Publikováno v:
Scientia
Background Dual-targeted anti-HER2 therapy significantly improves outcomes in HER2-positive breast cancer and could be beneficial in other HER2-positive cancers. JACOB’s end-of study analyses aimed to evaluate the long-term efficacy and safety of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b405a466248cd7cec2dc6bcf2cdfd68b
https://doi.org/10.1007/s10120-022-01335-4
https://doi.org/10.1007/s10120-022-01335-4
Autor:
Lionel Adès, Larisa Girshova, Vadim A. Doronin, María Díez-Campelo, David Valcárcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argiris Symeonidis, Achilles Anagnostopoulos, Eduardo Ciliao Munhoz, Uwe Platzbecker, Valeria Santini, Robert J. Fram, Ying Yuan, Sharon Friedlander, Douglas V. Faller, Mikkael A. Sekeres
Publikováno v:
Scientia
Pevonedistat; Chronic myelomonocytic leukemia Pevonedistat; Leucemia mielomonocítica crónica Pevonedistat; Leucèmia mielomonocítica crònica PANTHER is a global, randomized phase 3 trial of pevonedistat+azacitidine (n = 227) vs azacitidine monoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8838e72608b49d5e2a82c322c09cf86
https://doi.org/10.1182/bloodadvances.2022007334
https://doi.org/10.1182/bloodadvances.2022007334